Cadila receives USFDA approval for potassium chloride extended release tablets

Cadila has received USFDA approval for Potassium Chloride extended-release capsules to market the same in United States. The product is used to treat or prevent low amounts of potassium in the blood.

The prescribed product will be marketed in the strengths of 8 mEq (600 mg) and 10 mEq (750 mg). Potassium helps cells, kidneys, heart, muscles and nerves work properly. Some conditions that can lower the body’s potassium level include severe prolonged diarrhea and vomiting, hormone problems such as hyperaldosteronism, or treatment with water pills/diuretics.

Company Profile : Cadila Healthcare Ltd

Be the first to comment

Leave a Reply

Your email address will not be published.